Legal Notice
Trademark Disclaimer
GLP Watchdog is an independent editorial publication. We review and compare prescription weight loss medications and telehealth providers. Because we write about real products, we use their real brand names. This page explains who owns the trademarks we reference, why we use them, and what that means for you.
The short version
Wegovy®, Ozempic®, Rybelsus® and Saxenda® belong to Novo Nordisk A/S. Mounjaro®, Zepbound® and Foundayo® belong to Eli Lilly and Company. Everything else named on this site belongs to whoever owns it, and none of it belongs to us. We print these names because you cannot write about a drug without naming it — not because any of these companies endorses, sponsors, reviews or has any relationship with this register. Several of them would probably rather we did not.
Drug trademarks referenced on this site
The medications this register writes about, and who holds the mark on each.
| Mark | Owner |
|---|---|
| Wegovy® | Novo Nordisk A/S |
| Ozempic® | Novo Nordisk A/S |
| Rybelsus® | Novo Nordisk A/S |
| Mounjaro® | Eli Lilly and Company |
| Zepbound® | Eli Lilly and Company |
| Foundayo® | Eli Lilly and Company |
| Saxenda® | Novo Nordisk A/S |
| Victoza® | Novo Nordisk A/S |
| SELECT™ | Novo Nordisk A/S |
| STEP™ | Novo Nordisk A/S |
| SURMOUNT™ | Eli Lilly and Company |
Provider and program trademarks
The sellers in the register own their own names and logos. Being listed here is not a license they granted us; it is coverage, and it applies to companies that pay us and companies that do not.
| Mark | Owner |
|---|---|
| Hims® & Hers® | Hims & Hers Health, Inc. |
| Ro® | Roman Health Ventures Inc. |
| Found® | Findhealth, Inc. |
| Calibrate® | Calibrate Health, Inc. |
| Noom® | Noom, Inc. |
| WeightWatchers® / WW® | WW International, Inc. |
| Sequence® | WW International, Inc. |
| Eden® | Eden Health, Inc. |
| Mochi Health® | Mochi Health, Inc. |
Neither table is complete, and neither is meant to be. Any other mark appearing anywhere on this site belongs to its owner.
What that actually means
We are not the manufacturer. Nothing on this site is made, sold, shipped, prescribed or dispensed by us. We hold no inventory and fill no orders. If a page names a drug, we are describing someone else’s product.
We are not the provider. Every telehealth company in the register is a separate business we write about from the outside. Some pay us a commission when a reader signs up, which is disclosed on the row it applies to; none of them has any editorial control here.
We use brand names only to identify products. When we say “Wegovy” or “Mounjaro,” we mean the specific FDA-approved product sold under that name. This is known as nominative fair use: you can't meaningfully compare weight loss drugs without naming them.
Manufacturers have not endorsed our content. Nothing we publish has been reviewed, approved, or endorsed by Novo Nordisk, Eli Lilly, or any trademark holder. Any opinions, rankings, or evaluations represent our independent editorial judgment.
Reviews are our opinion, not the manufacturer's. Our provider rankings and drug guides reflect our scoring methodology and editorial perspective. They do not represent the views of any trademark holder.
Generic names versus brand names
Every prescription drug has both a chemical (generic) name and one or more brand names. The generic name identifies the active ingredient and is not a trademark. The brand name is a trademark owned by the manufacturer. We use both throughout the site, and they are not interchangeable in a legal sense.
- Semaglutide is the generic name for the active molecule sold by Novo Nordisk under the brand names Wegovy® (for weight management), Ozempic® (for type 2 diabetes), and Rybelsus® (oral formulation).
- Tirzepatide is the generic name for the active molecule sold by Eli Lilly under the brand names Mounjaro® (for type 2 diabetes) and Zepbound® (for weight management).
- Orforglipron is the generic name for the oral GLP-1 receptor agonist sold by Eli Lilly under the brand name Foundayo® (for chronic weight management).
- Liraglutide is the generic name for the molecule previously sold as Saxenda® (for weight management) and Victoza® (for type 2 diabetes).
When we write about “compounded semaglutide” or “compounded tirzepatide,” we are referring to the active pharmaceutical ingredient prepared by a licensed compounding pharmacy under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Compounded medications are not Wegovy®, Ozempic®, Rybelsus®, Mounjaro®, or Zepbound®. They are separate preparations that contain the same active molecule. We take care to make this distinction clear wherever we discuss compounded GLP-1 products.
Source of trademark information
Trademark ownership information on this page is based on public records from the United States Patent and Trademark Office. You can verify any U.S. trademark registration yourself using the USPTO Trademark Electronic Search System (TESS):
Trademark registrations change over time. If you notice an inaccuracy on this page, please let us know using the contact information below and we will correct it.
Reporting trademark concerns
If you are a trademark holder, an authorized agent of a trademark holder, or legal counsel representing a trademark holder, and you believe GLP Watchdog is using your mark inappropriately, please contact us at legal@glpwatchdog.org with the subject line Trademark Concern. Please include the specific mark, the registration number if applicable, the URL of the page in question, and a description of the concern. We review all trademark correspondence and will respond within 5 business days.
Related policies: Affiliate Disclosure · Methodology · About · Terms · Privacy
Last reviewed: April 2026. This notice is provided for informational purposes and is not legal advice.